Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$74.03

-3.26 (-4.22%)

, IONS

Ionis Pharmaceuticals

$72.69

-0.8 (-1.09%)

05:22
05/07/19
05/07
05:22
05/07/19
05:22

Piper more confident in estimates for Alnylam's Onpattro after doctor survey

Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Alnylam Pharmaceuticals (ALNY) with a $142 price target after surveying 16 physicians treating 490 hereditary transthyretin amyloidosis patients with polyneuropathy. Doctors have a "clear preference" for Alnylam's Onpattro over Onpattro and Ionis Pharmaceuticals' (IONS) Tegsedi, with efficacy, safety, and experience being cited, Tenthoff tells investors in a research note. Roughly two-thirds of existing and new gene silencer patients are prescribed Onpattro, says the analyst. Based on the survey results, the analyst is increasingly confident in his 2019 Onpattro sales estimates of $127M.

ALNY

Alnylam

$74.03

-3.26 (-4.22%)

IONS

Ionis Pharmaceuticals

$72.69

-0.8 (-1.09%)

  • 09

    May

  • 14

    May

  • 06

    Jun

  • 17

    Jun

  • 18

    Jun

ALNY Alnylam
$74.03

-3.26 (-4.22%)

05/01/19
PIPR
05/01/19
NO CHANGE
Target $142
PIPR
Overweight
Alnylam shares reacting to increased expense guidance, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff noted that Alnylam reported Q1 Onpattro sales of $26M, which beat his $14M estimate and the consensus forecast of $19M. Despite the Onpattro sales beat and trends that he said underscore the drug's "best-in-class profile," Tenthoff said the stock is reacting negatively to management having increased their 2019 expense guidance. The analyst, who raised his 2019 Onpattro sales forecast to $127M from $82M, keeps an Overweight rating and $142 price target on Alnylam. Near 11 am ET, Alnylam shares are down 4% to $85.49.
04/15/19
PIPR
04/15/19
NO CHANGE
Target $142
PIPR
Overweight
Lumasiran could give Alnylam 3 RNAi drugs approved by 2021, says Piper Jaffray
After Alnylam presented new Phase 2 open-label extension data for lumasiran in primary hyperoxaluria type 1 patients, Piper Jaffray analyst Edward Tenthoff said he believes that lumasiran could become Alnylam's third approved RNAi drug after the expected approval in 2020 of givosiran to combine with currently marketed Onpattro. The analyst, who projects lumasiran to launch in 2021 and for sales to exceed $1B by 2024, keeps an Overweight rating and $142 price target on Alnylam shares.
04/15/19
BMOC
04/15/19
NO CHANGE
Target $126
BMOC
Outperform
Alnylam price target raised to $126 from $119 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Alnylam to $126 and kept his Outperofrm rating after the company's presented Givosiran phase 3 data at EASL, also raising his probability of success estimate for the program to 100% from 70%. Based on the "clear, robust efficacy and reasonable safety for an ultra-rare disease with limited treatment options", the analyst believes that Givosiran's risk/benefit profile supports approval, adding that the already granted "breakthrough" designation for the program by the FDA and PRIME designation by the EMA should further facilitate approval. Do Kim expects the approval to take place in early 2020 after U.S. and E.U. regulators complete their rolling submissions in mid-2019.
04/15/19
NOMU
04/15/19
NO CHANGE
Target $62
NOMU
Reduce
Positive givosiran data largely priced into Alnylam, says Nomura Instinet
The "generally positive" givosiran data over the weekend, which is likely to support approval in the U.S. and Europe, is largely baked into shares of Alnylam Pharmaceuticals, Nomura Instinet analyst Christopher Marai tells investors in a research note. However, the small market opportunity and the inability to genetically identify patients has not been fully appreciated, adds the analyst. He estimates $239M in 2022 sales globally compared to the consensus at $299M. While the data suggest givosiran can reduce high acute attack rates to be more in line with less severe, more typical manifestation of the disease, chronic symptom improvement did not reach statistical significance, says Marai. He reiterates a Reduce rating on Alnylam with a $62 price target.
IONS Ionis Pharmaceuticals
$72.69

-0.8 (-1.09%)

04/22/19
BMOC
04/22/19
NO CHANGE
Target $96
BMOC
Outperform
Ionis Pharmaceuticals price target raised to $96 from $82 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Ionis Pharmaceuticals (IONS) to $96 and kept his outperform rating after including the risk-adjusted royalties for HTT-Rx in his model as part of the update on its partnership with Roche (RHHBY) disclosed last month. The analyst notes that the stock price has started to reflect the company's Huntington's disease opportunity based on the "potential for an accelerated path with Phase 2 data" and believes that his HTT-Rx projections could prove to be "conservative".
04/17/19
WELS
04/17/19
NO CHANGE
WELS
Outperform
Ionis pullback on Roche update a buying opportunity, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterated his Outperform rating on Ionis Pharmaceuticals (IONS) following an update today from partner Roche (RHHBY) on its HTT-ASO program for Huntington's disease, stating that he believes the update continues to support potential for accelerated approval filing pending efficacy data that should be updated by year end. When asked during its earnings call about the specific filing strategy of using phase 1 OLE data in comparison to the natural history data, Roche made no comment beyond reiterating that the company will get data, share data with regulators, and work on the fastest way to bring the therapy to patients, said Birchenough. The analyst, who recommends buying Ionis on weakness, added that Roche noted that the company has had initial promising discussion with regulators.
04/17/19
WELS
04/17/19
NO CHANGE
WELS
Wells says Ionis weakness on Roche Huntington's update a buying opportunity
04/09/19
CANT
04/09/19
INITIATION
Target $68
CANT
Neutral
Cantor starts Ionis at Neutral with Spinraza risks not priced in
Cantor Fitzgerald analyst Eliana Merle initiated coverage of Ionis Pharmaceuticals with a Neutral rating and $68 price target. Ionis is an RNA-platform company that has produced one of the largest pipelines in biotech, but its shares are up 50% year-to-date, Merle tells investors in a research note. The appreciation reflects high investor expectations for the base business and pipeline, says the analyst. Further, Merle thinks near-term competitive headwinds to Spinraza, Ionis' single largest revenue driver, are not reflected in the current valuation.

TODAY'S FREE FLY STORIES

XLE

Energy Select Sector SPDR

$61.29

-2.23 (-3.51%)

10:40
05/23/19
05/23
10:40
05/23/19
10:40
Options
Massive ratio put spread in Energy SPDR ETF adjust profitable position »

Massive ratio put spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAD

Acadia

$24.78

-0.33 (-1.31%)

, ALKS

Alkermes

$24.44

-0.61 (-2.44%)

10:39
05/23/19
05/23
10:39
05/23/19
10:39
Conference/Events
JPMorgan biotech analysts to hold an analyst/industry conference call »

Biotech Analysts Fye,…

ACAD

Acadia

$24.78

-0.33 (-1.31%)

ALKS

Alkermes

$24.44

-0.61 (-2.44%)

ITCI

Intra-Cellular

$13.49

0.41 (3.13%)

NBIX

Neurocrine

$78.73

-1.14 (-1.43%)

SAGE

Sage Therapeutics

$173.51

-1.49 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 05

    Jun

  • 27

    Sep

IDYA

IDEAYA Biosciences

$0.00

(0.00%)

10:37
05/23/19
05/23
10:37
05/23/19
10:37
Syndicate
IDEAYA Biosciences indicated to open at $14, IPO priced at $10 »

IDEAYA Biosciences (IDYA)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

CZR

Caesars

$8.96

-0.155 (-1.70%)

10:35
05/23/19
05/23
10:35
05/23/19
10:35
Options
Caesars put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
05/23/19
05/23
10:30
05/23/19
10:30
General news
EIA natural gas storage change for week ending May 17 »

Gas inventories 100 Bcf…

RTLR

Rattler Midstream

$0.00

(0.00%)

10:25
05/23/19
05/23
10:25
05/23/19
10:25
Syndicate
Breaking Syndicate news story on Rattler Midstream »

Rattler Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

10:25
05/23/19
05/23
10:25
05/23/19
10:25
Conference/Events
JPMorgan TMT analyst to hold an Analyst/Industry conference call »

TMT Sector Specialist…

AGR

Avangrid

$50.37

-0.04 (-0.08%)

10:23
05/23/19
05/23
10:23
05/23/19
10:23
Hot Stocks
Avangrid Renewables announces new wind contract with Dairyland »

Dairyland Power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

AMX

America Movil, also tag AMOV

$14.15

-0.19 (-1.33%)

10:20
05/23/19
05/23
10:20
05/23/19
10:20
Options
Call buyer opens a notable new position in American Movil »

Call buyer opens a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTLR

Rattler Midstream

$0.00

(0.00%)

, FANG

Diamondback Energy

$103.16

-5.71 (-5.24%)

10:19
05/23/19
05/23
10:19
05/23/19
10:19
Syndicate
Breaking Syndicate news story on Rattler Midstream, Diamondback Energy »

Rattler Midstream…

RTLR

Rattler Midstream

$0.00

(0.00%)

FANG

Diamondback Energy

$103.16

-5.71 (-5.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 23

    May

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
05/23/19
05/23
10:17
05/23/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
05/23/19
05/23
10:16
05/23/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUNW

Sunworks

$0.68

0.0226 (3.42%)

10:15
05/23/19
05/23
10:15
05/23/19
10:15
Hot Stocks
Sunworks wins contract to build 1 MW solar project for California school »

Sunworks announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTLR

Rattler Midstream

$0.00

(0.00%)

, FANG

Diamondback Energy

$102.97

-5.9 (-5.42%)

10:15
05/23/19
05/23
10:15
05/23/19
10:15
Syndicate
Rattler Midstream indicated to open at $17.50, IPO priced at $17.50 »

Rattler Midstream (RTLR),…

RTLR

Rattler Midstream

$0.00

(0.00%)

FANG

Diamondback Energy

$102.97

-5.9 (-5.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 23

    May

TSLA

Tesla

$197.24

5.85 (3.06%)

10:15
05/23/19
05/23
10:15
05/23/19
10:15
Periodicals
Musk says Tesla produced 900 Model 3s per day this week, Reuters reports »

Tesla has produced 900…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

SBUX

Starbucks

$76.11

-1.12 (-1.45%)

10:15
05/23/19
05/23
10:15
05/23/19
10:15
Options
Starbucks put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 25

    Jun

  • 09

    Jul

10:15
05/23/19
05/23
10:15
05/23/19
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

10:15
05/23/19
05/23
10:15
05/23/19
10:15
General news
Breaking General news story  »

Week of 5/17 EIA Natural…

CMG

Chipotle

$665.03

-41.02 (-5.81%)

, BLMN

Bloomin' Brands

$18.74

-1.46 (-7.23%)

10:12
05/23/19
05/23
10:12
05/23/19
10:12
On The Fly
Chipotle seen among restaurants most at risk from African swine fever pressure »

Shares of Chipotle…

CMG

Chipotle

$665.03

-41.02 (-5.81%)

BLMN

Bloomin' Brands

$18.74

-1.46 (-7.23%)

TXRH

Texas Roadhouse

$52.05

-2.96 (-5.38%)

HRL

Hormel Foods

$38.38

-1.1 (-2.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 13

    Jun

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 27

    Aug

  • 28

    Aug

  • 13

    Nov

ELAN

Elanco

$32.33

-0.055 (-0.17%)

, CTB

Cooper Tire

$28.35

-0.28 (-0.98%)

10:10
05/23/19
05/23
10:10
05/23/19
10:10
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

ELAN

Elanco

$32.33

-0.055 (-0.17%)

CTB

Cooper Tire

$28.35

-0.28 (-0.98%)

GT

Goodyear Tire

$14.59

-0.41 (-2.73%)

SCPL

SciPlay

$15.40

-0.06 (-0.39%)

TH

Target Hospitality

$10.74

-0.06 (-0.56%)

ALLO

Allogene Therapeutics

$28.29

-0.75 (-2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

QCOM

Qualcomm

$66.24

-3 (-4.33%)

, CMG

Chipotle

$665.03

-41.02 (-5.81%)

10:10
05/23/19
05/23
10:10
05/23/19
10:10
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

QCOM

Qualcomm

$66.24

-3 (-4.33%)

CMG

Chipotle

$665.03

-41.02 (-5.81%)

BLMN

Bloomin' Brands

$18.73

-1.47 (-7.28%)

SSL

Sasol

$24.66

-0.95 (-3.71%)

EXPE

Expedia

$115.63

-1.14 (-0.98%)

NTAP

NetApp

$58.89

-3.69 (-5.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 04

    Jun

  • 06

    Jun

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 09

    Jul

  • 31

    Jul

TGT

Target

$77.90

0.4 (0.52%)

, PM

Philip Morris

$85.84

0.38 (0.44%)

10:10
05/23/19
05/23
10:10
05/23/19
10:10
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

TGT

Target

$77.90

0.4 (0.52%)

PM

Philip Morris

$85.84

0.38 (0.44%)

BKNG

Booking Holdings

$1,726.43

-19.07 (-1.09%)

VRTX

Vertex

$171.22

-1.15 (-0.67%)

RACE

Ferrari

$141.66

-1.22 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 06

    Jun

  • 12

    Jun

10:10
05/23/19
05/23
10:10
05/23/19
10:10
General news
U.S. new home sales dropped 6.9% to 673k in April »

U.S. new home sales…

VRNT

Verint

$56.09

-5.12 (-8.36%)

10:07
05/23/19
05/23
10:07
05/23/19
10:07
Hot Stocks
Verint named Strong Sell at Spruce Point as M&A 'obscures' organic growth »

Shares of Verint (VRNT)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 20

    Jun

RHHBY

Roche

$0.00

(0.00%)

10:02
05/23/19
05/23
10:02
05/23/19
10:02
Hot Stocks
Roche announces FDA 510(k) clearance for cobas TV/MG test »

Roche announced U.S. FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 20

    Jun

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.